- Home
- / Avrobio
Avrobio
Stock Price
$1.4
2024-06-21
Market Capitalization
$5.2 M
2024-06-21
Avrobio Summary
Company Summary
- Overview
- Gene therapy has the potential to deliver dramatic disease modifying effects and potentially life-long cures from a single infusion of genetically-modified cells.
- Type
- Public
- Status
- Active
- HQ
- Cambridge, MA, US | view all locations
- Website
- http://www.avrobio.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Erik Ostrowski, Chief Financial Officer
Azadeh Golipour, Chief Technology Officer
Deanna Petersen, Chief Business Officer
LocationsView all
1 location detected
Cambridge, MA HQ
United States
One Kendall Square Building 300 Suite 201
Avrobio Financials
Summary Financials
- Net income (Q1, 2026)
- ($25.2M)
- Cash (Q1, 2026)
- $236.9M
- EBIT (Q1, 2026)
- ($27.3M)
- Enterprise value
- ($227.3M)